Singular Genomics Systems (NASDAQ:OMIC – Get Rating) and Akoya Biosciences (NASDAQ:AKYA – Get Rating) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, dividends, profitability, analyst recommendations, institutional ownership, risk and valuation.
Profitability
This table compares Singular Genomics Systems and Akoya Biosciences' net margins, return on equity and return on assets.
Get
Singular Genomics Systems alerts:
| Net Margins | Return on Equity | Return on Assets |
| Singular Genomics Systems | N/A | -29.16% | -25.41% |
| Akoya Biosciences | -99.49% | -70.53% | -37.60% |
Earnings and Valuation
This table compares Singular Genomics Systems and Akoya Biosciences' revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio |
| Singular Genomics Systems | N/A | N/A | -$98.77 million | ($1.25) | -1.69 |
| Akoya Biosciences | $54.92 million | 7.45 | -$42.94 million | ($1.85) | -5.83 |
Akoya Biosciences has higher revenue and earnings than Singular Genomics Systems. Akoya Biosciences is trading at a lower price-to-earnings ratio than Singular Genomics Systems, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a summary of recent ratings and target prices for Singular Genomics Systems and Akoya Biosciences, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
| Singular Genomics Systems | 1 | 2 | 0 | 0 | 1.67 |
| Akoya Biosciences | 0 | 0 | 5 | 0 | 3.00 |
Singular Genomics Systems currently has a consensus target price of $3.50, suggesting a potential upside of 65.88%. Akoya Biosciences has a consensus target price of $17.80, suggesting a potential upside of 65.12%. Given Singular Genomics Systems' higher possible upside, analysts plainly believe Singular Genomics Systems is more favorable than Akoya Biosciences.
Insider & Institutional Ownership
56.3% of Singular Genomics Systems shares are owned by institutional investors. Comparatively, 34.6% of Akoya Biosciences shares are owned by institutional investors. 22.6% of Singular Genomics Systems shares are owned by company insiders. Comparatively, 9.2% of Akoya Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Volatility and Risk
Singular Genomics Systems has a beta of 0.84, suggesting that its share price is 16% less volatile than the S&P 500. Comparatively, Akoya Biosciences has a beta of 0.97, suggesting that its share price is 3% less volatile than the S&P 500.
Summary
Singular Genomics Systems beats Akoya Biosciences on 8 of the 13 factors compared between the two stocks.
About Singular Genomics Systems
(Get Rating)
Singular Genomics Systems, Inc., a life science technology company, develops next generation sequencing and multiomics technology to build products for researchers and clinicians to advance science and medicine. The company manufactures G4 Instrument, a benchtop next generation sequencer to produce genetic sequencing results, as well as associated menu of consumable kits. It also offers PX Integrated Solution that combines single cell analysis, spatial analysis, genomics, and proteomics in one integrated instrument providing a versatile multiomics solution. The company has partnerships with Agilent Technologies, Dovetail Genomics, Lexogen, New England Biolab, QIAGEN, Roche, Twist Bioscience, and Watchmaker Genomics to validate their library preparation kits on the G4, as well as the Broad Institute of MIT and Harvard to connect the G4 to Terra platform, a data platform. Singular Genomics Systems, Inc. was incorporated in 2016 and is headquartered in La Jolla, California.
About Akoya Biosciences
(Get Rating)
Akoya Biosciences, Inc., a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow. It also provides PhenoCycler and PhenoImager reagents; and biopharma services. In addition, the company offers Proxima, a cloud-based platform to store, analyze, and share spatial data; inForm Tissue, an automated image analysis software package for accurately visualizing and quantifying biomarkers in tissue sections; Phenoptr, which provides functions that consolidate and analyze output tables created by inForm software; and phenoptrReports, a software that generates shareable reports and visualizations based on the phenoptr output in an intuitive front-end GUI. The company was incorporated in 2015 and is headquartered in Marlborough, Massachusetts.
Receive News & Ratings for Singular Genomics Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Singular Genomics Systems and related companies with MarketBeat.com's FREE daily email newsletter.
